Kristi Rosa | Authors


OS Benefit Suggested for Frontline IO Versus TKIs in Metastatic Non–Clear Cell RCC

February 11, 2021

A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.

Beti-Cel Shows Good Activity in Transfusion-Dependent Children With Beta-Thalassemia

February 10, 2021

Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.

DFS Prolonged With Adjuvant Osimertinib Despite Prior Adjuvant Chemo in EGFR+ NSCLC

January 29, 2021

In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.